XML 90 R75.htm IDEA: XBRL DOCUMENT v3.25.2
Segment, Geographic and Other Revenue Information - Schedule of Segment Reporting Information by Segment - Footnotes (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 29, 2025
Jun. 30, 2024
Jun. 29, 2025
Jun. 30, 2024
Segment Reporting Information [Line Items]        
Restructuring charges and certain acquisition-related costs $ (18) $ 1,254 $ 660 $ 1,356
Certain legal matters, net [1] 422 169 564 377
Restructuring Charges, Acquisition Related Costs and Implementation Costs 54 1,364 727 1,532
ViiV [Member]        
Segment Reporting Information [Line Items]        
Dividend income   (74) (111) (135)
Biopharma [Member] | ViiV [Member]        
Segment Reporting Information [Line Items]        
Dividend income $ (73)      
Paxlovid [Member]        
Segment Reporting Information [Line Items]        
Favorable adjustment for government emergency use authorization inventory returned to the company during the period       771
Paxlovid [Member] | Biopharma [Member]        
Segment Reporting Information [Line Items]        
Favorable adjustment for government emergency use authorization inventory returned to the company during the period       771
Reconciling Items [Member] | Certain Significant Items [Member]        
Segment Reporting Information [Line Items]        
Restructuring Charges, Acquisition Related Costs and Implementation Costs   $ 1,200 $ 670 $ 1,200
[1] The amounts for the second quarter and first six months of 2025 primarily include certain product liability and other legal expenses. The amounts for the second quarter and first six months of 2024 primarily included certain product liability expenses related to products discontinued and/or divested by Pfizer.